Heart failure substantially affects the quality of life of patients and imposes notable social and economic burdens. Despite the beneficial effects of cardiac rehabilitation, global participation rates remain low. Recent advances in wearable biometric technologies may improve patient adherence through real-time monitoring and personalized feedback. This study aimed to develop and evaluate an exercise-support program that integrates wearable devices to enhance rehabilitation outcomes in patients with heart failure. An innovative and practical cardiac rehabilitation program combined with a wearable device was developed based on patients and physicians' feedback. A multicenter randomized controlled clinical trial was designed to evaluate the safety and effectiveness of the application in patients with heart failure in Japan from October 2022 to January 2025. Compared with traditional exercise-monitoring applications, the developed application offers an array of features that are designed to foster patient engagement and promote long-term adherence. These features include (1) individualized goal setting, (2) direct communication with healthcare providers, (3) education on heart failure through instructional videos, (4) automated motivational feedback, and (5) a curated library of research summaries on cardiac rehabilitation and self-care. Patients who meet the inclusion criteria (including those aged ≥18 years with a clinical diagnosis of heart failure) will be randomly assigned to one of two groups as follows: the integrated exercise-support app group or the standard care group, in which only a wearable device was implemented. The change in peak VO2 at 12 weeks, adjusted for baseline and allocation factors, will be analyzed as the primary endpoint. The secondary outcomes include quality-of-life measures and re-hospitalization rates. Data analysis will follow the intention-to-treat principle, with results reported as two-tailed 95 % confidence intervals and corresponding p-values.This study was approved by the relevant institutional ethics committee (approval number: DB23-001; iRCT: 2032230388). Informed consent will be obtained from all participants before study participation. The results of the study will be disseminated through peer-reviewed publications and presented at relevant scientific meetings.
Background:The relationship between left ventricular diastolic dysfunction (LVDD) and paroxysmal atrial fibrillation (PAF) remains unclear because of a lack of standard measures to evaluate LVDD. Accordingly, we examined the association between the prevalence of PAF and each LVDD grade determined according to the latest American Society of Echocardiography guidelines. Methods and Results:In all, 2,063 patients without persistent AF who underwent echocardiography at Saitama Municipal Hospital from July 2016 to June 2017 were included in the study. Patients were divided into LVDD 6 categories: No-LVDD (n=1,107), Borderline (n=392), Grade 1 (n=204), Indeterminate (n=62), Grade 2 (n=254), and Grade 3 (n=44). PAF was documented in 111 (10.0%), 81 (20.7%), 28 (13.7%), 6 (9.7%), 52 (20.5%), and 24 (54.5%) patients in the No-LVDD, Borderline, Grade 1, Indeterminate, Grade 2, and Grade 3 categories, respectively. PAF prevalence was higher in patients with Grade 3 LVDD across the whole study population. Subgroup analyses showed that the prevalence of PAF increased with increased LVDD grade in patients with reduced left ventricular ejection fraction. This relationship was significant in multivariate analysis including various patient characteristics. Conclusions:LVDD severity determined on the basis of the latest echocardiographic criteria was associated with the prevalence of PAF. The present findings shed light on the development of new therapeutic markers for PAF.
Background/Objectives: Left atrial diverticula (LADs) have been reported to potentially be associated with arrhythmic substrates, thromboembolic events, and complications during catheter ablation for atrial fibrillation (AF), but their clinical significance remains unclear. This study aimed to assess the prevalence, location, and potential relationship with complications during AF catheter ablation using preoperative CT. Methods: This study included 595 consecutive patients undergoing AF catheter ablation at Keio University Hospital from April 2021 to February 2024. Preoperative ECG-gated cardiac MDCT scans were analyzed to assess the presence and location of the LAD. Intraoperative adverse events were documented, and the association between the LAD and mechanical complications, such as a cardiac perforation and tamponade, was evaluated. Results: A total of 595 patients undergoing catheter ablation for AF or atrial tachycardia (AT) were included, with 210 (35.3%) found to have an LAD. No significant differences in age, sex, body mass index, or arrhythmia type were observed between patients with or without an LAD. LADs were most commonly located in the anterior region of the right superior pulmonary vein (53.4% of cases), followed by the anterior region of the left superior pulmonary vein (15% of cases). Perioperative complications occurred in 12 cases (2.0%), with 7 in the LAD group and 5 in the non-LAD group. Mechanical complications were observed exclusively in the LAD group (n = 4), with three of the cases associated with LADs. In all cases, LADs were present in the anterior region of the right superior pulmonary vein and were caused by the accidental insertion of an angiographic catheter into the LAD during pulmonary venography before insertion of the ablation catheter into the left atrium. However, all cases were hemodynamically stable, and the procedures were completed as planned. Conclusions: LADs are a more common anatomical structure than generally recognized and may be associated with mechanical complications during AF catheter ablation. Identifying the presence of an LAD on preoperative CT is crucial for predicting potential risks.
Intracardiac electrocardiograms were recorded during a narrow QRS supraventricular tachycardia following atrial extrastimulation. What is the mechanism?